{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:01:53Z","timestamp":1788915713451,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100033","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:07:39Z","timestamp":1722506859000},"page":"100033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-121X","authenticated-orcid":false,"given":"Koji","family":"Nagafuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikiyo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bneo.2024.100033_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993","volume":"108","author":"Lazarus","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100033_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2024.100033_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100033_bib4","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","article-title":"Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia","volume":"87","author":"Brisco","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100033_bib6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2012-07-379016","article-title":"How I treat older patients with ALL","volume":"122","author":"Gokbuget","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2024.100033_bib7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2024.100033_bib8","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100033_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bneo.2024.100033_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-8722-6-14","article-title":"Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)","volume":"6","author":"Nagafuji","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/ejh.13268","article-title":"Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia","volume":"103","author":"Nagafuji","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100033_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100033_bib13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100033_bib14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100033_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100033_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2011.77","article-title":"Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults","volume":"8","author":"Schafer","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.bneo.2024.100033_bib17","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dhedin","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2024.100033_bib18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A\u00a0pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.bneo.2024.100033_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/10428190109057984","article-title":"Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia","volume":"41","author":"Cataland","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bneo.2024.100033_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2024.100033_bib21","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12185-010-0670-1","article-title":"Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia","volume":"92","author":"Kikuchi","year":"2010","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100033_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2401245","volume":"13","author":"Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2024.100033_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2024.100033_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bneo.2024.100033_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/leu.2015.230","article-title":"Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2024.100033_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2024.100033_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100033_bib30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cam4.2096","article-title":"The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: an IMPACT Cohort study","volume":"8","author":"Gupta","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bneo.2024.100033_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100033_bib32","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2024.100033_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2021.11.016","article-title":"Hypersensitivity to Pegylated E. coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group","volume":"162","author":"Brigitha","year":"2022","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.bneo.2024.100033_bib34","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.23.01797","article-title":"Continuous PEGasparaginase dosing reduces hypersensitivity reactions in pediatric ALL: a Dutch Childhood Oncology Group ALL11 randomized trial","volume":"42","author":"van der Sluis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100033_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/bloodadvances.2022007791","article-title":"The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study","volume":"7","author":"Aldoss","year":"2023","journal-title":"Blood advances"},{"issue":"24","key":"10.1016\/j.bneo.2024.100033_bib36","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 Clinical Trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100033_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.leukres.2018.03.010","article-title":"Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"68","author":"Ribera","year":"2018","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jha2.224","article-title":"Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults","volume":"2","author":"Patel","year":"2021","journal-title":"EJHaem"},{"issue":"6","key":"10.1016\/j.bneo.2024.100033_bib39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.bneo.2024.100033_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100033_bib41","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"2","key":"10.1016\/j.bneo.2024.100033_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100033_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:57:27Z","timestamp":1737773847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000335"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100033","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100033"}}